
Dermata Therapeutics (DRMA) Stock Forecast & Price Target
Dermata Therapeutics (DRMA) Analyst Ratings
Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%
Dermata Therapeutics (DRMA) has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.
This aggregate rating is based on analysts' research of Dermata Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
This aggregate rating is based on analysts' research of Dermata Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Dermata Therapeutics (DRMA) Analyst Forecast & Price Prediction
Get the latest Dermata Therapeutics (DRMA) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis
Start investing in Dermata Therapeutics (DRMA)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Dermata Therapeutics (DRMA) Forecast
Analysts have given Dermata Therapeutics (DRMA) a Strong Buy based on their latest research and market trends.
According to 2 analysts, Dermata Therapeutics (DRMA) has a Strong Buy consensus rating as of Jun 16, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.
Wall Street analysts have set a price target of $8.50, reflecting a 0.00% increase from the current stock price.
Financial analysts have set a price target of $8.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.